Eton Pharmaceuticals vs Rhythm Pharmaceuticals
ETON and RYTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ETON and RYTM compare
Rhythm Pharmaceuticals is the larger company, worth 4.3 times as much as Eton Pharmaceuticals ($7.6B against $1.8B).
Eton Pharmaceuticals grew revenue faster over the last twelve months (101% versus 53.5% for Rhythm Pharmaceuticals).
Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.3% compared with −85.6% at Rhythm Pharmaceuticals.
Eton Pharmaceuticals scores higher on the StockData Score (12 against 5 for Rhythm Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ETON | RYTM |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $7.6B |
| Share price | $61.45 | $109.86 |
| Change, 1 year | 248% | 10.0% |
| Change, 5 years | 1248% | 967% |
| Beta (5Y) | 0.87 | 1.40 |
| Employees | 44 | 414 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 40.4× | – |
| P/S | 12.5× (better) | 31.5× |
| P/B | 20.2× (better) | 73.4× |
| EV/EBITDA | 37.8× | – |
| P/FCF | 46.0× | – |
| FCF yield | 2.2% | – |
| Fair value | $33.43 | $31.52 |
| Margin of safety | −83.8% (better) | −249% |
| Growth | ||
| Revenue growth (TTM) | 101% (better) | 53.5% |
| Revenue growth, 5Y average | 360% | – |
| Profitability | ||
| Gross margin | 69.2% | 89.0% (better) |
| Operating margin | 28.8% (better) | −83.6% |
| Net margin | 35.3% (better) | −85.6% |
| FCF margin | 27.1% | – |
| Return on equity | 90.6% (better) | −451% |
| Return on invested capital | 115% | – |
| Financial health | ||
| Debt / equity | 0.27 (better) | 1.03 |
| Net debt / EBITDA | −0.71 | – |
| Interest coverage | – | −10.9× |
| Current ratio | 1.79 | 3.45 (better) |
| Altman Z-score | 16.49 (better) | 15.83 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 74.0% | 112% |
| Held by insiders | 5.6% | 1.1% |
| Insider net buying, 12 months | −$34.8M (better) | −$36.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.4% | 17.1% |
Go deeper
- ETON stock overview
- ETON income statement
- ETON valuation and score
- RYTM stock overview
- RYTM income statement
- RYTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.